Quote:

---

This is only regarding the PD-L1 expression. Ohm would know to what degree the 350 mg dose can help with macrophages, traveling cancer cells, etc.

---

350mg is an inadequate dose. Which is why Progenics shelved the drug. It was the concentrated formulation of leronlimab that allowed us to do doses weekly without excessive number of injections. With 350mg you get 85% receptor occupancy, very similar to the 84% of maraviroc. Maraviroc has been not quite good enough to get approval in anything other than HIV. More importantly is the half life. Maraviroc has a half-life between 14 and 18 hours so the occupancy decreases a bit between daily doses. Leronlimab at 350mg has a half-life of 3.7 days which means there's a quite significant drop in leronlimab between weekly doses. As the amount of leronlimab drops so would receptor occupancy.